Creating a green and healthy base: Healthy Element is expected to win an excellent award for Shenzhen's sponge city construction project

Time Posted：2021-10-22 23:08

Since Shenzhen was approved as a pilot city for national sponge city construction in 2016, it has formed a "seven-pronged" model for sponge city construction. By the end of 2020, the area of the built-up area in the city that met the requirements of the sponge city was 276 square kilometers, accounting for 28.3% of the total built-up area. While exceeding the national task requirements, it has also played a significant role in alleviating urban waterlogging and reducing non-point source pollution. Such impressive achievements are inseparable from the active cooperation and implementation of major enterprises in Shenzhen. According to publicly available data, Shenzhen has more than 400 enterprises related to "sponge city" construction, far ahead of the rest of the country. Recently, in order to continuously promote the sponge city construction work in Shenzhen, the Shenzhen Sponge City Construction Office organized the 2021 sponge city construction fund reward review work. HealthGen's wholly-owned subsidiary, Shenzhen Haibin Pharmaceutical Co., Ltd.'s Pingshan Pharmaceutical Industrialization Base, won the "Excellent Construction Award for Sponge City Construction Projects" and the reward for the construction of sponge facilities in newly built social capital projects (including demolition and reconstruction) with its green and healthy project "Haibin Pharmaceutical Factory Area". Sponge city is an important measure for cities to implement the concept of ecological civilization construction and the requirements of green development. It is conducive to promoting the systematic nature of urban infrastructure construction, and also conducive to achieving multiple goals such as repairing urban water ecology, nurturing urban water resources, improving urban water environment, ensuring urban water safety, and reviving urban water culture, building a city into a community of life where humans and nature coexist harmoniously. Since its establishment, HealthGen Pharmaceutical Group has always adhered to the mission and purpose of "For Health, For Tomorrow" and "Making Good Medicines with Care", focusing on innovative high-barrier complex preparations such as inhalation administration, antibody technology, sustained-release microspheres, and lipid microemulsions. It has formed a relatively complete enterprise technological innovation network combining production, learning, and research. At the same time, HealthGen attaches great importance to environmental protection, adheres to the development concept of green, healthy, and sustainable development, sets annual environmental goals, strengthens the monitoring of energy consumption, pollutant emissions, and other environmental protection information during production and operation, continuously improves environmental management performance based on monitoring results, continuously improves environmental management level, and refers to the practices of leading international peers to carry out pollutant emission reduction and energy-saving transformation planning, actively responding to China's macro vision of "achieving carbon neutrality by 2060". In terms of management system, HealthGen's production enterprises have obtained the international ISO14001 certification, and strictly follow the system requirements for annual system supervision audits and three-year recertification audits. The environmental impact assessment work and the "three simultaneous" system of the group's production subsidiaries have achieved 100% coverage, that is, the facilities for pollution prevention in construction projects should be designed, constructed, and put into operation simultaneously with the main project. In addition, the group's production subsidiaries have fully established self-monitoring programs, and hired qualified third-party testing institutions to conduct quarterly and annual testing of various wastewater and exhaust gas discharge outlets, comprehensively ensuring the compliance of emissions from various production enterprises. As of September 2021, HealthGen's subsidiaries had no major environmental pollution accidents or environmental administrative penalty accidents throughout the year. The initial rainwater collection rate, the discharge rate of production process wastewater and domestic sewage, the exhaust gas treatment rate, the noise detection rate, and the harmless treatment rate of solid waste were all 100%. Today, in order to cope with the challenges of climate change and answer the question of common prosperity, green development has also become one of the ways to promote high-quality urban development and common prosperity. In 2021, HealthGen continued to improve energy use efficiency, and checked against the national "Catalogue of Eliminated High-Energy-Consuming and Backward Electromechanical Equipment", eliminated backward equipment, adopted energy-saving equipment, gradually reduced factory energy consumption, and actively created a low-energy-consuming production enterprise. As one of the city's builders, HealthGen will always adhere to the principle of healthy development that benefits society, encourage its production subsidiaries to continuously upgrade environmental protection equipment and optimize production processes, and jointly promote green development.

Universal slow-onset disease prevention and treatment to help achieve common prosperity: Healthy Yuan & Lizhu Group's Huangshan District slow-onset disease drug distribution is steadily advancing

Time Posted：2021-10-14 18:40

This year marks the beginning of China's 14th Five-Year Plan and the first year of the comprehensive promotion of rural revitalization. As a pharmaceutical company, while striving for enterprise development, we also give full play to our own advantages, go deep into the grassroots level, actively assume social responsibilities, solve practical problems for patients with chronic diseases, and actively contribute to the realization of common prosperity.

Public Notice on the 2021 Self-Monitoring of Soil Conditions at Jiaozuo Jiankangyuan Bioproducts Co., Ltd.

Time Posted：2021-10-09 16:16

Completion of Environmental Protection Acceptance Public Notice for the Health Yuan Biomedicine Research Institute Project, Henan Health Yuan Biomedicine Research Institute Co., Ltd.

Time Posted：2021-09-28 17:35

Public Notice: Environmental Impact Report for Jiaozuo Jiankangyuan Bioproducts Co., Ltd.'s 400-ton/year Erythromycin Thiocyanate Pharmaceutical Intermediate Project

Time Posted：2021-09-26 17:51

The environmental impact report for the "Jiaozuo Jiankangyuan Biopharmaceutical Co., Ltd. 400-ton annual output of erythromycin thiocyanate pharmaceutical intermediate project" has been completed and a review meeting has been held to solicit opinions from experts and the public.

China's COVID-19 vaccine V-01 enters Phase III clinical trials in the Philippines

Time Posted：2021-08-30 23:25

A recombinant fusion protein COVID-19 vaccine (V-01) developed and produced in China has been approved for Phase III clinical trials in the Philippines. The V-01 vaccine was jointly developed by the Institute of Biophysics, Chinese Academy of Sciences, and CSPC Pharmaceutical Group, located in Guangdong Province, southern China.

Good news! Lizhu Group's restructured novel coronavirus fusion protein vaccine has entered Phase III clinical trials

Time Posted：2021-08-27 17:37

LIZHU Group's holding company, Zhuhai LIZHU Monoclonal Antibody Biotechnology Co., Ltd. (hereinafter referred to as "LIZHU Monoclonal Antibody"), has launched global Phase III clinical trials (hereinafter referred to as "Phase III clinical trials") for its "recombinant novel coronavirus fusion protein vaccine" (hereinafter referred to as "V-01"). LIZHU Monoclonal Antibody recently submitted a Phase III clinical trial application to the Philippine FDA, which has been approved. The first subject was enrolled in the Philippines on August 25, 2021. Currently, LIZHU Monoclonal Antibody has submitted Phase III clinical trial applications to more than 10 countries worldwide.

Excellent information disclosure quality! Health Yuan receives the highest A-level rating from the Shanghai Stock Exchange for its information disclosure work.

Time Posted：2021-08-19 15:48

Recently, the Shanghai Stock Exchange announced the results of its evaluation of the information disclosure work of Shanghai main board listed companies for 2020-2021. After a comprehensive assessment, Health-Yuan (stock code: 600380.SH) received the highest rating of A (Excellent). This result reflects the company's phased achievements in a series of measures, including continuously strengthening its information disclosure management, standardized operations, continuously improving the quality of information disclosure, and enriching investor communication and interaction.